Extended Data Fig. 6: Induction of polyfunctional CD8+ and CD4+ T cell responses.
From: Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial

Percent of neoantigen OLP-pools that induced a positive CD8+ or CD4+ T cell response by production of IFNγ, TNFα, or IL-2 secretion. Patients listed in blue for the adjuvant cohort, purple for the metastatic cohort. Metastatic setting n = 3 patients, adjuvant setting n = 3 patients.